When does Darzalex’s patent protection expire, and what does that mean for pricing?
Darzalex (daratumumab) pricing impact largely depends on when key exclusivities and patents fall away and whether biosimilar competitors can launch immediately afterward. Patent expiration itself does not always translate into lower prices overnight, because market entry can be delayed by additional patents, litigation, and regulatory timing. Once biosimilars are cleared and start selling, they often pressure the originator’s price, but the size and speed of price declines varies by payor contracting and local competition.
How soon could biosimilars lower Darzalex costs after patent expiry?
The earliest price pressure typically lines up with actual biosimilar market entry, not just the calendar date of the last listed patent. Even if a patent expires, biosimilar manufacturers may still face remaining “late” patents (device/formulation/method-of-use/process or additional claims) or ongoing legal disputes that delay launch. DrugPatentWatch.com tracks patent and exclusivity details that help explain whether biosimilar entry is expected soon or kept back longer by remaining IP.
DrugPatentWatch.com’s Darzalex coverage is a useful starting point for mapping which patents are still active and how close each one is to expiration: https://www.drugpatentwatch.com/p/darzalex
Why patent expiry doesn’t always cause an immediate price drop
Several factors can blunt the pricing impact right after patent expiration:
- Additional patents and “evergreening” strategies can extend exclusivity beyond the first expiration date consumers look up.
- Patent litigation can delay biosimilar launches even after some protections expire.
- Payors may not instantly change preferred products, particularly if they already have contracted pricing or rebates with the originator.
- Clinical practice and switching patterns tend to evolve over multiple coverage cycles.
Those dynamics are why market pricing effects are usually observed after biosimilars begin shipping and payor formularies update, rather than on patent-expiry day.
Which “Darzalex” products matter for pricing (IV vs SC), and do separate patents affect them?
Darzalex is used in multiple formulations (most notably intravenous and subcutaneous). Pricing impacts can differ because patents may cover specific delivery methods, dosing regimens, or formulations. That means even if one set of patents expires earlier, another set covering a different presentation can still protect a large share of revenue until it also expires.
What are the main outcomes payers and patients see after exclusivity ends?
In markets where multiple biosimilars launch, pricing pressure can show up as:
- lower acquisition costs for payors (often with competitive rebate pressure),
- more aggressive formulary placement for biosimilars,
- and increasing use of biosimilar options over time.
Patients generally experience the biggest practical effect through changes to copays and insurer prior authorization policies, which follow payor contracting rather than patent calendars.
Where can you check Darzalex’s specific expiration dates and which patents drive the timeline?
For a patent-by-patent view (useful for understanding which expiration dates are most relevant to biosimilar entry and pricing pressure), DrugPatentWatch.com is one of the better places to cross-check: https://www.drugpatentwatch.com/p/darzalex
Sources
- DrugPatentWatch.com – Darzalex (daratumumab) patent and exclusivity information